WHO Drug Information Vol. 17, No. 3, 2003
(2003; 85 pages) View the PDF document
Table of Contents
Open this folder and view contentsRational Use of Drugs
Open this folder and view contentsSafety and Efficacy Issues
Close this folderIndividual Drugs
View the documentThe role of statins in primary prevention
View the documentA strategy to reduce cardiovascular disease by more than 80%?
Open this folder and view contentsAspects of Quality Assurance
Open this folder and view contentsConsultation Document
Open this folder and view contentsRegulatory and Safety Action
Open this folder and view contentsRegulatory Challenges
Open this folder and view contentsATC/DDD Classification
View the documentProposed International Nonproprietary Names: List 89
View the documentAnnex 1 - Procedure for the selection of recommended international nonproprietary names for pharmaceutical substances*
View the documentAnnex 2 - General principles for guidance in devising international nonproprietary names for pharmaceutical substances*
View the documentAnnexe 1 - Procédure a suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques
View the documentAnnexe 2 - Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques*
View the documentAnexo 1 - Procedimiento de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas
View the documentAnexo 2 - Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas*
 

A strategy to reduce cardiovascular disease by more than 80%?

Heart attacks, stroke, and other preventable cardiovascular diseases kill or seriously affect many populations. Western diet and lifestyle increase levels of risk factors and their combined effects have made these diseases common. Cardiovascular disease can be avoided or delayed, but the necessary changes to Western diet and lifestyle are not practicable in the short term. Randomized trials show that drugs to lower three risk factors - low density lipoprotein (LDL) cholesterol, blood pressure, and platelet function (with aspirin) - reduce the incidence of ischaemic heart disease (IHD) events and stroke. Evidence that lowering serum homocysteine (with folic acid) reduces the risk of these diseases is largely observational but still compelling.

With this in mind, a meta-analysis has recently been carried out in the United Kingdom (1) to determine the combination of drugs and vitamins to achieve prevention of cardiovascular disease with minimal adverse effects as a single daily polypill (2). The strategy would simultaneously reduce four cardiovascular risk factors: low-density lipoprotein cholesterol, blood pressure, serum homocysteine, and platelet function, regardless of pretreatment levels.

The following polypill formulations are proposed:

• a statin: e.g. atorvastatin or simvastatin;

• three blood pressure lowering drugs: e.g. a thiazide, beta blocker, and angiotensin converting enzyme (ACE) inhibitor;

• folic acid; and

• aspirin.


The polypill is estimated to reduce IHD events by 88% and stroke by 80%. One-third of people taking this pill from age 55 would therefore benefit - gaining on average about 11 years of life free from an IHD event or stroke. Summing the adverse effects of the components observed in randomized trials showed that the polypill would cause symptoms in 8-15% of people depending on the precise formulation. The authors propose that this strategy could largely prevent heart attacks and stroke if taken by everyone aged 55 and older and everyone with existing cardiovascular disease. It would be acceptably safe and with widespread use would have a greater impact on the prevention of disease in the Western world than any other single intervention.

A large preventive effect would require intervention in everyone at increased risk irrespective of the risk factor levels; intervention on several reversible causal risk factors together; and reducing these risk factors by as much as possible.

A low-cost polypill could use generic components that are no longer subject to patent protection. This formulation does not have the lowest rate of adverse effects, but even if about 10% of people were intolerant of the formulation it would still have considerable public health merit. Those found to be intolerant could be prescribed alternatives to avoid the side effects. Controlled trials of different formulations of the polypill would provide direct estimates of acceptability.

The preventive strategy outlined is radical. But the authors argue that a formulation that prevented all cancer and was safe would undoubtedly be widely used, and one that prevented more than 80% of cardiovascular disease would be even more important because such deaths are more common than cancer deaths. It is also pointed out that in Western society the risk factors are high and everyone is at risk. The diseases they cause are common and often fatal and there is much to gain and little to lose by the widespread use of these drugs. No other preventive method would have so great an impact on public health in the Western world.

Reference:

1. Law, M.R., Wald, N.J., Rudnicka, A.R. Quantifying effect of statins on low density lipoprotein cholesterol ischaemic heart disease, and stroke: systematic review and meta-analysis. British Medical Journal, 326: 1423 (2003).

2. Wald, N.J., Law, M.R. A strategy to reduce cardiovascular disease by more than 80%. British Medical Journal, 326: 1419-1422 (2003).

 

to previous section to next section
 

Last updated: May 3, 2013